Resources Repository
-
ArticlePublication 2020Health Gains & Financial Risk Protection Afforded by Public Financing of Selected Malaria Interventions in Ethiopia: An ECEA
This article, published in the Malaria Journal, aims to estimate the expected health and financial …
This article, published in the Malaria Journal, aims to estimate the expected health and financial risk protection (FRP) benefits of universal public financing of key malaria interventions in Ethiopia. An extended cost-effectiveness analysis (ECEA) is used to estimate the potential health and FRP benefits of publicly financing a 10% increase in artemisinin-based combination therapy (ACT), long-lasting insecticide-treated bed nets (LLIN), indoor residual spraying (IRS), and a hypothetical malaria vaccine. The results indicate that ACT, LLIN,…
Priority Setting/Ethics | Health/Medicine | Social Determinants | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Sub-Saharan Africa -
ArticlePublication 2016Health and Economic Benefits of Public Financing of Epilepsy Treatment in India
This study uses extended cost-effectiveness analysis (ECEA) to evaluate the impact of three scenarios of …
This study uses extended cost-effectiveness analysis (ECEA) to evaluate the impact of three scenarios of publicly financed national epilepsy programs in India that provide (1) first line antiepilepsy drugs (AEDs), (2) first- and second-line AEDs, and (3) first- and second-line AEDs and surgery. Outcome measures include disability-adjusted life years (DALYs) averted, and cost per DALY averted. Economic benefit measures estimated include out-of-pocket (OOP) expenditure averted and money-metric value of insurance. All three scenarios represent a…
Priority Setting/Ethics | Health/Medicine | Chronic Disease/Risk | Microsimulation | Cost-Effectiveness Analysis | Economics/Finance | Asia & Pacific -
ArticlePublication 2017Extended Cost-Effectiveness Analyses of Cardiovascular Risk Factor Reduction Policies
This chapter summarizes lessons learned from three extended cost-effectiveness analyses (ECEAs) conducted on cardiovascular disease …
This chapter summarizes lessons learned from three extended cost-effectiveness analyses (ECEAs) conducted on cardiovascular disease (CVD) risk factor reduction policies, specifically highlighting new insights into the differential impacts of well-established CVD prevention interventions. Tobacco taxation, salt reduction, and primary prevention of CVD in high-risk individuals remain widely regarded as best buys in global noncommunicable disease policy, and the ECEAs confirm the findings of previous CEAs, namely, that these interventions will likely result in large health…
Priority Setting/Ethics | Health/Medicine | Chronic Disease/Risk | Evidence Synthesis | Cost-Effectiveness Analysis | Global -
BookPublication 2019Non-Communicable Disease Prevention: Best Buys, Wasted Buys, Contestable Buys
Non-communicable diseases (NCDs) are the leading cause of death worldwide, and the majority of these …
Non-communicable diseases (NCDs) are the leading cause of death worldwide, and the majority of these deaths occur in low- and middle-income countries. This book provides practical guidelines and lessons learned through real-world case studies. It is intended to be informative to NCD program managers, policy officers and decision-makers in low- and middle-income countries, who need to comparatively assess interventions for the prevention and control of NCDs.The authors emphasize the importance of context in NCD control…
Priority Setting/Ethics | Health/Medicine | Chronic Disease/Risk | Cost-Effectiveness Analysis | Technology Assessment | Infectious Diseases | Health Systems | Policy/Regulation | Global -
ArticlePublication 2019Cost-Effectiveness of Clinic, Home, or Ambulatory Blood Pressure Measurement for Hypertension Diagnosis
This study compared three methods of blood pressure (BP) measurement for diagnosing hypertension in primary …
This study compared three methods of blood pressure (BP) measurement for diagnosing hypertension in primary care settings, accounting for the possibility of false-positive (white-coat hypertension) and false-negative (masked hypertension) clinic measurements. Outcomes included quality-adjusted life years (QALYs) and lifetime costs associated with clinic BP measurement, home BP monitoring, and ambulatory blood pressure monitoring (ABPM) under two scenarios: positive and negative initial screening. Data were from published literature, public data sources, and expert input. In the…
Mathematical Models | Health/Medicine | Chronic Disease/Risk | Cost-Effectiveness Analysis | Clinical Care | North America -
Teaching PackPublication, Teaching Resource 2022Teaching Pack: Extended Cost-Effectiveness Analysis
This teaching pack, curated by the Center for Health Decision Science, features videos introducing extended …
This teaching pack, curated by the Center for Health Decision Science, features videos introducing extended cost-effectiveness analysis (ECEA) and detailing how it is conducted, and assembles ECEA publications and teaching materials. In addition to the videos, this teaching pack includes a glossary and tutorial. Videos include: Video 1. Introduction to ECEA (~2 min) Video 2. Quantifying Health Benefits (~4 min) Video 3. Private Expenditures Averted (~3 min) Video 4. Financial Risk Protection (~5 min) Video 5.…
Priority Setting/Ethics | Health/Medicine | Social Determinants | Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Health Systems | Policy/Regulation | Economics/Finance | Global -
ArticlePublication 2019Assessment of the Feasibility and Cost of Hepatitis C Elimination in Pakistan
This study investigates the feasibility and cost of hepatitis C virus (HCV) elimination in Pakistan …
This study investigates the feasibility and cost of hepatitis C virus (HCV) elimination in Pakistan using a decision analytical model and microsimulation techniques from 2015 to 2030. Various scenarios, including the status quo and seven elimination strategies, were evaluated based on Pakistan-specific variables. Main outcomes included trends in HCV prevalence, mortality, disability-adjusted life-years, and total costs of HCV care. Results suggest that to achieve HCV elimination by 2030, significant scale-up of testing and treatment is…
Decision Analysis | Health/Medicine | Chronic Disease/Risk | Infectious Diseases | Asia & Pacific -
Resource PortalWeb Portal, Teaching Resource 2021Disease Control Priorities (DCP3)
DCP3 includes a comprehensive review of the efficacy, effectiveness, and cost-effectiveness of priority health interventions …
DCP3 includes a comprehensive review of the efficacy, effectiveness, and cost-effectiveness of priority health interventions with the goal of influencing program design and resource allocation at global and country levels. DCP3 includes nine individual volumes, with the first eight structured around packages of conceptually related interventions, and the ninth providing an overview of main findings. Publicly available resources include journal articles and reports, both DCP3 and non-DCP3 related, as well as presentations, working papers, and book…
Priority Setting/Ethics | Health/Medicine | Chronic Disease/Risk | Costing Methods | Evidence Synthesis | Cost-Effectiveness Analysis | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Mental Health | Injuries/Accidents | Health Systems | Policy/Regulation | Science/Technology | Global | High School | College | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Policy Translation -
ArticlePublication 2018Should We Treat Acute Hepatitis C? A Decision and Cost-Effectiveness Analysis
This study examines the potential benefits of treating acute hepatitis C virus (HCV) infection compared …
This study examines the potential benefits of treating acute hepatitis C virus (HCV) infection compared to deferring treatment until the chronic phase, utilizing a microsimulation model. By projecting long-term outcomes such as quality-adjusted life years (QALYs) and costs, the analysis evaluates the cost-effectiveness of initiating therapy during the acute phase. Results indicate that treating acute HCV increases QALYs by 0.02 and costs by $483 per patient not at risk of transmitting HCV, yielding an incremental…
Decision Analysis | Health/Medicine | Chronic Disease/Risk | Microsimulation | Cost-Effectiveness Analysis | Infectious Diseases | North America